GlassScriptPhysician profile
Connie S Ball
NPI 1528176393
$2,211.72
in general payments reported to CMS, 2019-2025
15 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $561 · 2021: $235 · 2022: $253 · 2023: $154 · 2024: $13.31 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $707.13 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $472.62 | 2019-2023 | Arexvy |
| Pfizer INC. | $271.96 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.54 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $136.02 | 2021-2025 | Airsupra |
| Esperion Therapeutics, INC. | $122.58 | 2020 | |
| Abbvie INC. | $116.60 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $89.80 | 2022 | |
| Sunovion Pharmaceuticals INC. | $37.18 | 2019 | |
| Lilly USA, LLC | $33.26 | 2021 | |
| Sanofi-Aventis U.S. LLC | $27.55 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.77 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $13.70 | 2019 | |
| Evoke Pharma, INC. | $13.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.